欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子抑制剂 > CytoskeletalSignaling > WAY-262611

浏览历史

S82019

WAY-262611

源叶(MedMol) 95%
  • 英文名:
  • WAY-262611
  • 别名:
  • CAS号:
  • 1123231-07-1
  • 分子式:
  • C20H22N4
  • 分子量:
  • 318.4155
  • 核磁/质谱:
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
源叶(MedMol) S82019-5mg 95% ¥590.00元 8 - - - EA 加入购物车
源叶(MedMol) S82019-10mg 95% ¥780.00元 5 - - - EA 加入购物车
源叶(MedMol) S82019-50mg 95% ¥2465.00元 3 - - - EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 提示:详情请下载说明书。
  • 产品描述: WAY-262611 (BML-WN110, Compound 5) 是一种 beta-catenin (β-Catenin) 的激动剂,可增加骨形成速率,在TCF-荧光素酶测定中的EC50值为0.63 μM。WAY-262611 也是一种 dickkopf 1 (DKK1) 的抑制剂
  • 靶点: DKK1;β-Catenin(TCF-Luciferase assay):0.63 μM(EC50);Wnt/beta-catenin
  • 体外研究:
    WAY-262611, the DKK1 inhibitor, blocks DKK1 and restores the GDF5 reduced MMP13 gene expression
  • 体内研究:
    WAY-262611 has excellent pharmacokinetic properties and shows a dose dependent increase in the trabecular bone formation rate in ovariectomized rats following oral administration
  • 细胞实验: Cell lines: Surplus human chondrocytes Concentrations: 0.01 μM, 0.1 μM, 1 μM Incubation Time: 21 days Method: Chondrocytes are resuspended at 1.25×106 cells/ml in basic differentiation media (BDM) consisting of DMEM high glucose supplemented with 100 nM dexamethasone, 1× insulin-transferrin-selenous acid premix (ITS), 1.0 mg/ml human serum albumin supplemented with 5.0 μg/ml linoleic acid, 14 μg/ml L-ascorbic acid 2-phosphate and 1× Penicilline-Streptomycin. The cell suspension is divided into aliquots of 200 μl to each well of an uncoated flat bottom 96-well plate. The plate is centrifuged at 1,500 rpm for 5 min and incubated for 48 h at 37°C in 5% CO2 and 90% relative humidity to allow for pellet formation. After 48 h the culture medium is changed to BDM supplemented with appropriate growth factors (GFs); 2, 10, 100 or 200 ng/ml recombinant GDF5, 50 ng/ml recombinant Wnt3a, 0.5 μM GSK3b inhibitor CHIR-99021, 0.01, 0.1 or 1 μM DKK1 inhibitor WAY-262611. Medium is changed three times per week for 21 days,
  • 动物实验: Animal Models: OVX rats Dosages: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg; 2 mg/kg Administration: Oral gavage; IV
  • 参考文献:
    1. Jeffrey C Pelletier, et al. (1-(4-(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine: a wingless beta-catenin agonist that increases bone formation rate. J Med Chem. 2009 Nov 26;52(22):6962-5. 2. L Enochson, et al. GDF5 reduces MMP13 expression in human chondrocytes via DKK1 mediated canonical Wnt signaling inhibition. Osteoarthritis Cartilage. 2014 Apr;22(4):566-77.
  • 溶解性: Soluble  in  DMSO、Ethanol、H2O
  • 保存条件: -20℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 3.141 ml 15.703 ml 31.406 ml
    5 mM 0.628 ml 3.141 ml 6.281 ml
    10 mM 0.314 ml 1.57 ml 3.141 ml
    50 mM 0.063 ml 0.314 ml 0.628 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。